↓ Skip to main content

The end of a dogma: the safety of doxycycline use in young children for malaria treatment

Overview of attention for article published in Malaria Journal, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
10 X users
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
146 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The end of a dogma: the safety of doxycycline use in young children for malaria treatment
Published in
Malaria Journal, April 2017
DOI 10.1186/s12936-017-1797-9
Pubmed ID
Authors

Tiphaine Gaillard, Sébastien Briolant, Marylin Madamet, Bruno Pradines

Abstract

Anti-malarial drug resistance to chloroquine and sulfadoxine-pyrimethamine has spread from Southeast Asia to Africa. Furthermore, the recent emergence of resistance to artemisinin-based combination therapy (ACT) in Southeast Asia highlights the need to identify new anti-malarial drugs. Doxycycline is recommended for malaria chemoprophylaxis for travel in endemic areas, or in combination with the use of quinine for malaria treatment when ACT is unavailable or when the treatment of severe malaria with artesunate fails. However, doxycycline is not used in young children under 8 years of age due to its contraindication due to the risk of yellow tooth discolouration and dental enamel hypoplasia. Doxycycline was developed after tetracycline and was labelled with the same side-effects as the earlier tetracyclines. However, recent studies report little or no effects of doxycycline on tooth staining or dental enamel hypoplasia in children under 8 years of age. In the United States, the Centers for Disease Control and Prevention have recommended the use of doxycycline for the treatment of acute and chronic Q fever and tick-borne rickettsial diseases in young children. It is time to rehabilitate doxycycline and to recommend it for malaria treatment in children under 8 years of age.

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mozambique 1 <1%
Brazil 1 <1%
Unknown 144 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 15%
Student > Master 16 11%
Other 15 10%
Student > Bachelor 15 10%
Student > Ph. D. Student 12 8%
Other 28 19%
Unknown 38 26%
Readers by discipline Count As %
Medicine and Dentistry 53 36%
Pharmacology, Toxicology and Pharmaceutical Science 12 8%
Biochemistry, Genetics and Molecular Biology 9 6%
Agricultural and Biological Sciences 6 4%
Immunology and Microbiology 6 4%
Other 14 10%
Unknown 46 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2024.
All research outputs
#1,805,303
of 25,168,110 outputs
Outputs from Malaria Journal
#299
of 5,869 outputs
Outputs of similar age
#34,212
of 315,741 outputs
Outputs of similar age from Malaria Journal
#13
of 136 outputs
Altmetric has tracked 25,168,110 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,869 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,741 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 136 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.